Company news
Imugene Ltd news in 2022
Imugene Ltd's news releases, calls and decks from 2022, newest first.
CHECKVacc Data Presented at the 2022 SABC Symposium
December 8, 2022
First Patient Dosed in VAXINIA Intravenous Cohort 2
December 4, 2022
Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
November 13, 2022
Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
November 11, 2022
Imugene onCARlytics with blinatumomab SITC presentation
November 10, 2022
Europe Patent granted for iNKT Cell Therapy Platform
November 6, 2022
First patient dosed in VAXINIA intratumoral cohort 2
October 30, 2022
Preclinical trial of ALA iNKT therapy and IMU onCARlytics
September 26, 2022
First patient IV dosed in VAXINIA Phase 1 clinical trial
September 20, 2022
OGTR grants VAXINIA DIR licence allowing trial expansion
September 19, 2022
Prospectus for the issue of institutional placement options
September 16, 2022
Imugene announces a$80 million institutional placement
September 12, 2022
Imugene doses first patient in nextHERIZON Phase 2 trial
September 7, 2022
Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
August 31, 2022
Annual Report and Appendix 4E
August 30, 2022
First cohort 3 patient dosed in clinical trial of checkvacc
August 9, 2022
Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
August 7, 2022
Final HER-Vaxx Phase 2 Trial Overall Survival Results
June 26, 2022
Imugene doses first patient in vaxinia phase 1 trial
May 17, 2022
IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
May 9, 2022
Clarification Announcement
May 3, 2022
Termination of Supply Agreement
May 2, 2022
Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
March 23, 2022
Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
March 22, 2022
Imugene HER-Vaxx Clinical Trial Collaboration with Merck
March 14, 2022
Oncolytic Virotherapy CF33 Patent Granted in Japan
January 30, 2022
PD1-Vaxx Clinical Trial Supply Agreement with Roche
January 28, 2022
HER-Vaxx Immunotherapy Patent Granted in Europe
January 27, 2022
Imugene Receives $6.54 million R&D Tax Incentive
January 6, 2022
South Korea HERVaxx Patent Grant
January 5, 2022
Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
January 3, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 15 slides · Nov 17, 2022
- Investor Presentation (November 2022)
Investor deck · 31 slides · Nov 15, 2022